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Abstract
Background: Among non-motor symptoms of Parkinson’s disease (PD), anxiety occurs in up to 67% of patients. Clinically, PD patients report worsening of 
tremors in anxiogenic situations. Objective: The aim of this study was to evaluate the association between motor symptoms and anxiety in PD patients and 
compare their performances with those of healthy volunteers. Methods: Fifteen volunteers with PD and 15 healthy volunteers without clinically significant 
psychiatric disorders were evaluated. Both groups were subjected to a simulated public speaking test (SPST). The following parameters were measured: visual 
analog mood scale (VAMS), items related to tremors of UPDRS, bradykinesia tests, blood pressure, and heart rate. Results: Results of repeated measures ANOVA 
indicated a significant effect on group × phase interaction (F3.7,105.6 = 2.56; p = 0.046) for VAMS anxiety factor. Regarding tremors, ANOVA indicated significant 
differences in group × phase interaction (F4.5,121 = 2.88; p = 0.021) and between the groups (F1,27 = 45.88, p < 0.001), with differences in the anticipatory phase, 
performance, and post-speech, compared with those in the baseline. There were no significant differences between the groups with regard to other factors of 
VAMS, physiological measurements, and bradykinesia. Discussion: Worsening of tremors occurred during SPST, particularly in phases with higher anxiety scores. 
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Introduction
Parkinson’s disease (PD) is one of the most common neurological 
syndromes and is the main cause of Parkinsonism among older 
people. In Brazil, approximately 3.3% of the population above age 64 
has PD1. Although diagnosis is based on motor symptoms (rigidity, 
bradykinesia, resting tremor, and postural instability), the presence 
of non-motor symptoms is common; these symptoms potentiate 
the disability in PD and may have a major impact on the health and 
quality of life of patients2. 
Among the non-motor symptoms, anxiety affects up to 67% of 
patients with PD3. Notwithstanding, this topic is still little explored. 
Studies that have evaluated the prevalence of anxiety disorders in PD 
patients have reported a high prevalence of anxiety without other 
symptoms4, which indicates the difficulty in characterizing anxiety in 
PD. Symptoms of anxiety are often related to motor symptoms5 and 
the off period in patients with motor fluctuations6, which suggests a 
close association between these symptoms. 
Experimental tests used to induce anxiety in healthy volunteers 
are available. One of these tests is the simulated public speaking test 
(SPST), which was developed and validated by Mcnair et al.7 and 
subsequently modified by Guimarães et al.8 This clinical anxiety 
model involves making a speech in front of a video camera; this test 
has been used in several pharmacological studies in cases of normal 
anxiety and anxiety disorders, and its validity has been confirmed9,10.
In the clinical setting, patients complain of worsening of tremors 
in anxiogenic situations; however, the association between these 
factors remains to be elucidated. Therefore, this study aimed to 
assess anxiety symptoms (subjective and physiological) and motor 
symptoms (tremor and bradykinesia) induced in patients with PD 
using SPST, and their performances were compared with those of 
healthy individuals without PD.
Methods
Local and participants
Fifteen subjects with PD were selected in the Movement Disorders 
Outpatient Clinic of the Clinics Hospital of the Medical School of 
Ribeirão Preto at the University of São Paulo (FMRP-USP), and 
15 volunteers without PD were included in the control group. The 
inclusion criteria of the PD group were the following: idiopathic 
PD, Hoehn and Yahr score of 1–3, absence of marked cognitive 
impairment according to clinical evaluation, absence of treatment 
with benzodiazepines and antidepressants, use of stable doses of 
antiparkinsonian drugs for at least 30 days. The exclusion criteria 
were the following: atypical parkinsonism, presence of dementia, 
and/or current psychiatric diagnosis according to the DSM-IV 
criteria. For the control group, the inclusion criteria were absence 
of marked cognitive impairment according to clinical evaluation 
and Mini Mental State Exam11, and absence of treatment with 
benzodiazepines and antidepressants. Elderly people with current 
psychiatric diagnosis were excluded. Experiments were performed 
in the psychopharmacology laboratory of FMRP-USP. This study was 
approved by the local ethics committee (process number – CAAE: 
10082712.7.0000.5440) and the volunteers signed an informed 
consent to participate. Study performed according to the Declaration 
of Helsinki.
Measurements
The following parameters were measured:
Visual analog mood scale (VAMS)12 translated and adapted 
to Portuguese13: this scale consisted of 16 pairs of adjectives with 
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opposite meanings, and participants indicated how they felt about 
each of these adjectives at the time of the test. The scale items were 
divided into four groups: anxiety, sedation, cognitive impairment, 
and discomfort.
Tapping test (TT): bradykinesia test in which participants were 
asked to lightly touch two points that are 30 cm apart. Participants 
completed 10 cycles (one cycle corresponding to touching both sides 
of the segment) and the time to perform the task was measured on 
both sides14.
Pronation–supination (PS): bradykinesia test was performed 
with the participants in a sitting position, in which they were asked 
to perform 20 cycles of alternately and lightly touching the back of 
their thighs with the back and palm of their hands14.
Tremors: tremors were measured according to items 20 and 21 of 
the unified Parkinson’s disease rating scale (UPDRS)15. A score was 
obtained from the sum of resting tremors and posture/movement 
in the upper limbs. 
Procedures
STPS is an experimental model to induce anxiety. In this model, 
the participant is asked to prepare a speech on a neutral subject 
that is recorded and analyzed by a specialist. During the speech, 
the subject remains seated in front of a monitor that shows his/
her image, which is captured by a camera positioned above the 
screen7. In this study, the volunteers were asked to perform a 4-min 
speech on the theme “the transport system in your city”. During 
the procedure, physiological measurements (blood pressure and 
heart rate) were obtained at different phases of the experiment. 
Table 1 summarizes the procedure. All PD patients were evaluated 
in the on state.
Results
Participants
Table 2 describes the clinical and demographic data of the study 
sample, consisting of 15 PD patients and 15 control subjects without 
PD. There were no differences in sex, age, education, and cognition 
between the groups. The mean score on total UPDRS was 33.73 
(SD: ±9.92). In relation to antiparkinsonian treatment of PD group, 
most of the patients were using levodopa (n = 14), either alone or in 
combination with other medications. Other medications prescribed 
for PD treatment were pramipexole (n = 9), amantadine (n = 3), and 
selegiline (n = 3). 
Table 1. Timetable of the experimental session (SPST)
Time (min) Phases Procedure
- 0:30
- 0:15 Baseline (B) VAMS, TT, PS, HR, BP, Tremor
0 Pre-stress (P) VAMS, TT, PS, HR, BP, Tremor
+ 0:10 Instrutions about the SPST
+ 0:12 Speech preparation
+ 0:14 Antecipatory speech (A) VAMS, TT, PS, HR, BP, Tremor
+ 0:25 Start speech
+ 0:27 Speech performance (S) VAMS, TT, PS, HR, BP, Tremor
+ 0:33 Continuation of speech
+ 0:35 End of speech
+ 0:40 Post-stress 1 (F0) VAMS, TT, PS, HR, BP, Tremor
+ 0:55 Post-stress 2 (F1) VAMS, TT, PS, HR, BP, Tremor
VAMS: visual analog mood scale; TT: tapping test; PS: pronation-supination; HR: heart rate; 
BP: blood pressure.
Statistical analysis 
Clinical and demographic data related to sample pairing were 
statistically analyzed using Student’s t-test for continuous data 
with normal distribution, non-parametric Mann–Whitney test for 
continuous data with non-normal distribution, and chi-square test 
for nominal data. 
The differences between the scores of VAMS factors, physiological 
parameters (blood pressure and heart rate), tremor, and bradykinesia 
were evaluated using repeated measures analysis of variance 
(ANOVA) and the phases, groups, and group × phase interactions 
were evaluated. When sphericity was violated, the degrees of freedom 
were corrected using the Huynh–Feldt epsilon.
Statistical analysis was performed using the SPSS software version 
21.0 at a significance level of p < 0.05. 
Table 2. Clinical and demographic data stratified by the groups
PD Control p
N 15 15
Male/Female 10/5 9/6 0.705
Age in years (SD) 61.0 (±2.04) 63.2 (±2.04) 0.439
Years of education (SD) 7.8 (±4.24) 9.9 (±4.31) 0.190
MMSE (SD) 26.8 (±2.73) 27.9 (±1.75) 0.187
Levodopa equivalent dose (SD) 736.67 (±400.61) - -
SD: standard deviation; MMSE: Mini Mental State Exam.
Psychological and physiological anxiety measures
Repeated measures ANOVA indicated a significant effect on phase 
(F3.7,105.6 = 7.77; p < 0.001) and group × phase interaction (F3.7,105.6 = 
2.56; p = 0.046) for VAMS anxiety factor (Figure 1). However, no 
difference was found between the groups (F1.28 = 0.27, p = 0.608). 
With regard to other VAMS factors, there was a significant effect of 
phase on mental sedation (F4.1,114.9 = 3.32; p = 0.012), physical sedation 
(F4.1,114.3 = 4.70; p = 0.001), and other feelings (F4.1,115.4 = 2.55; p = 
0.042). However, there were no significant effects of these parameters 
on group × phase interaction and the groups.
Repeated measures ANOVA showed a significant effect of phase 
(F5,140 = 4.59, p = 0.001) on heart rate without differences between 
the groups or group × phase interaction. Moreover, there were no 
differences in systolic or diastolic blood pressure between the phases, 
groups, or group × phase interaction.
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Figure 1. Changes in VAMS anxiety factor induced by SPST, measured in 
15 PD patients and 15 healthy subjects. The phases of the experimental 
session are: B-basal; P-pretest; A-anticipation; S-speech performance; F1-
-post-speech measures 1; F2-post-speech measures.
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Tremor and bradykinesia
Repeated measures ANOVA indicated a significant effect of phase 
on tremors (F4.5,121 = 2.42; p = 0.046), group × phase interaction 
(F4.5,121 = 2.88; p = 0.021) and group (F1,27 = 45.88; p < 0.001). The 
test of contrasts between the phases indicated significant differences 
between P and A phases (F1,28 = 6.06, p = 0.020). Results of the paired 
Student’s t-test indicated differences between phases A (t = –3.09; p 
= 0.008), S (t = –2.61; p = 0.018), and F0 (t = –2.35; p = 0.034) and 
phase P (Figure 2).
In the bradykinesia tests, repeated measures ANOVA indicated 
a significant effect of phase for both PS (F1.6,44.4 = 10.91; p < 0.001) 
and TT (F2,55.5 = 29.86; p < 0.001) tests without a significant effect on 
group and group × phase interaction.
In situations of anxiety, tremors may be one of the signs of 
anxiety, even in healthy individuals. Therefore, tremor in patients 
with PD could be potentiated in anxiogenic situations. Physiologic 
tremors primarily occur in cases of anxiety and stress, and the use 
of beta-blockers can be indicated in more severe cases and before 
important events24. 
With regard to pathophysiological mechanisms, the regions 
commonly involved in tremors are the thalamus, basal ganglia, and 
most of the cortical area via excitatory and inhibitory pathways. 
Furthermore, the cerebellum and locus coeruleus are a part of this 
complex mechanism of the motor system24. It is of note that these 
areas are also directly associated with mood symptoms25 and anxiety 
in PD26, thereby corroborating the influence of non-motor symptoms 
in tremors. 
The limitations of this study include the use of UPDRS items 
alone as a measure to evaluate tremors. As this was an initial study, 
we sought to assess motor symptoms in general, and an increase 
in the number of assessments would greatly increase the duration 
of assessment at each stage of STPS. Moreover, a study is being 
conducted using accelerometry to evaluate tremors using more 
objective data. We would like to highlight STPS could be used in 
future studies as an experimental anxiety model to assess the effect 
of drugs on tremors induced or exacerbated by anxiogenic situations 
in patients with PD.
In conclusion, this study showed worsening of tremors during 
SPST, particularly in phases with higher anxiety scores. 
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Figure 2. Changes in tremor score during SPST. * p < 0.05, Student’s t test 
for paired samples (compared with fase P).
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Discussion
Our findings indicate worsening of tremors in phases of higher 
anxiety scores (phases A and S) during STPS. This result confirms 
the hypothesis that tremors in PD patients worsen in anxiogenic 
situations. In addition, there was a statistically significant difference 
in the group × phase interaction between the study groups, which 
suggests anxiety behavior differences between patients with PD and 
healthy controls.
Several studies have reported an increase in anxiety symptoms 
in PD patients, even if these symptoms do not characterize a specific 
anxiety disorder4. These anxiety disorders include social anxiety 
disorder, which has a high prevalence in patients with PD16,17, possibly 
by a two-way mechanism, because on the one hand, symptoms of 
anxiety potentially increase in social-interaction settings, thus leading 
to increased tremors, and on the other hand, motor symptoms result 
in negative self-evaluation and increased anxiety.
A recent study reported a correlation among increased levels of 
anxiety, impaired ability to perform activities of daily living, severity 
of motor symptoms, and presence of motor fluctuations18. Another 
study evaluated the correlation between virtual reality-induced 
anxiety and freezing of gait and concluded that anxiety had a strong 
influence on freezing of gait19, thus strengthening the role of the 
limbic system in the motor symptoms of PD19,20. Most studies that 
have assessed the association between anxiety and motor symptoms 
primarily studied motor fluctuations that occurred throughout 
the day and their association with mood swings and anxiety20-23; 
however, their results were inconclusive, confirming the complexity 
of this topic.
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